Literature DB >> 16086130

Olanzapine therapy in hallucinatory visions related to Bonnet syndrome.

M Coletti Moja1, E Milano, S Gasverde, M Gianelli, M T Giordana.   

Abstract

Charles Bonnet syndrome (CBS) is characterised by the triad of complex visual hallucinations, ocular pathology causing visual deterioration and preserved cognitive status. We report a case of a 62-year-old man with a brief history of visual hallucinations. The patient complained of amaurosis with optic nerve atrophy in his left eye and a severe impairment of visual acuity in the right and suddenly experienced complex, vivid, elaborate and coloured visual hallucinations persisting long after eye closure and stopping during sleep. The patient maintained his insight, criticising these visions as unreal and felt distressed by them. Hallucination onset was 3 days before hospital admission. No cognitive impairment and no diseases apart from prostatic adenoma treated with alpha-lythic therapy were reported. Neurological examination and neuroimaging data were normal. Therapy with olanzapine (OLZ) 5 mg/day led to a progressive clearance of visual hallucinations in seven days and was gradually reduced and withdrawn. Three months later the visions reappeared and OLZ 5 mg/day yielded a persisting remission so that at the follow-up examination after 1 year on therapy the patient is still asymptomatic. To date, no established treatment for CBS is stated and in some patients the hallucinations fade spontaneously; in our case an antipsychotic therapy with OLZ was effective while generally anticonvulsant drugs with different mechanism of action such as carbamazepine, valproate and gabapentin are proposed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16086130     DOI: 10.1007/s10072-005-0455-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  10 in total

1.  Visual hallucinations: differential diagnosis and treatment.

Authors:  Ryan C Teeple; Jason P Caplan; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

2.  Cases: Charles Bonnet syndrome: visual loss and hallucinations.

Authors:  M L Jackson; Joseph Ferencz
Journal:  CMAJ       Date:  2009-08-04       Impact factor: 8.262

3.  Charles Bonnet syndrome in cranio-maxillofacial surgery: case report.

Authors:  Thomas Gander; Heinz-Theo Lübbers; Wolfgang Zemann; Christine Jacobsen
Journal:  Oral Maxillofac Surg       Date:  2013-03-05

Review 4.  The Charles Bonnet Syndrome: a Systematic Review of Diagnostic Criteria.

Authors:  Ali G Hamedani; Victoria S Pelak
Journal:  Curr Treat Options Neurol       Date:  2019-07-25       Impact factor: 3.598

5.  Charles Bonnet Syndrome in a Patient With Acute Glaucoma Following Carotid Endarterectomy.

Authors:  Andrew A Huffer; Hoon C Jung; Gale L Tang
Journal:  Neurohospitalist       Date:  2022-04-20

6.  Charles Bonnet Syndrome With Superimposed Delirium.

Authors:  Chelsea Karson; Christopher Kang; Brittany Albrecht; Geoffrey Levin
Journal:  Cureus       Date:  2022-08-01

Review 7.  Charles Bonnet syndrome: two case reports and review of the literature.

Authors:  Alberto Lerario; Andrea Ciammola; Barbara Poletti; Floriano Girotti; Vincenzo Silani
Journal:  J Neurol       Date:  2013-02-05       Impact factor: 4.849

8.  Visual Hallucinations in an Old Patient after Cataract Surgery and Treatment.

Authors:  Halil Ozcan; Atakan Yucel; Orhan Ates
Journal:  Eurasian J Med       Date:  2016-02

9.  A low dose of risperidone resolved Charles Bonnet syndrome after an unsuccessful trial of quetiapine: a case report.

Authors:  Sultan H Alamri
Journal:  Neuropsychiatr Dis Treat       Date:  2018-03-20       Impact factor: 2.570

Review 10.  Hallucinations Experienced by Visually Impaired: Charles Bonnet Syndrome.

Authors:  Linda Pang
Journal:  Optom Vis Sci       Date:  2016-12       Impact factor: 1.973

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.